Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as “GLS” on Friday, January 14, 2022 and...
Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with...
With the prevalence of fad diets, food shaming and resulting guilt, leading health experts advise against villainizing specific food groups and moving to flexibility and...
Plenity® is transforming weight management with a clinically proven approach made from naturally derived building blocks As Chief Nutrition Officer, Bauer will focus on educating healthcare...
Gelesis’ new commercial manufacturing facility is now producing Plenity® at large scale, enabling supply to meet the growing demand Gelesis announced today that leading U.S. direct-to-patient...
New paper describes the first superabsorbent hydrogel technology made from naturally derived building blocks designed to address obesity and gut related conditions by emulating compositional and...
Chief Scientific Officer Elaine Chiquette, Pharm.D., Named Among the Top 25 Women Leaders in Biotechnology Elizabeth Pash, MS, RD, LDN, Honored by Academy of Nutrition and Dietetics for...
Building on the successful beta launch of its first product Plenity®, Gelesis aims to transform weight management. Gelesis developed a novel biomimetic therapeutic platform that has yielded...
Capstar Special Purpose Acquisition Corp. (NYSE:CPSR.U; CPSR; CPSR WS) (the “Company”) today announced that, as expected, on May 25, 2021 it received a notice from the New York Stock Exchange...
AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Capstar Special Purpose Acquisition Corp. (the “Company”), today announced the pricing of its initial public offering of 24,000,000 units at a...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관